HSP40

PF3D7_1437900 (HSP40) is the sole canonical cytosolic type I J-domain co-chaperone of P. falciparum and functions as the essential Hsp40 partner of the parasite chaperone PfHsp70-1 in heat-shock defense and asexual intraerythrocytic replication (PMID:21191678, PMID:40627776). It stimulates the ATPase activity of PfHsp70-1 through its HPD motif, suppresses protein aggregation on its own, and cooperates with PfHsp70-1 to fold and rescue substrate proteins with higher efficiency than the human Hsp40–Hsp70 ortholog pair, aided by high substrate-binding affinity and a slow dissociation rate that keeps clients folding-competent (PMID:21191678, PMID:32893851). Mechanistically, HSP40 delivers specific clients to PfHsp70-1: it binds and stabilizes the ribonucleotide reductase small subunit PfR2, thereby supporting dNTP synthesis and DNA replication, and disrupting the HSP40–PfHsp70-1 interaction destabilizes PfR2, lowers dNTP levels, and arrests replication (PMID:40938117). The protein is farnesylated, a modification that controls its membrane attachment and its interactions with client pathways (PMID:34182772). Conditional knockdown confirms an essential and specialized role: depletion produces a cell-cycle progression defect with reduced nuclear replication and downregulation of DNA replication/repair pathways, sensitizes parasites to DNA-replication inhibition, and impairs survival of febrile temperatures, yet does not mitigate general proteotoxic stress from artemisinin or proteasome inhibition, indicating a role dedicated to heat-shock survival rather than generic protein quality control (PMID:40627776).

1. 2010 High

   Establishing whether the parasite's single canonical cytosolic Hsp40 actually functions as a bona fide Hsp70 co-chaperone was the first requirement for placing it in a chaperone pathway.

   Evidence Heat-shock induction Western blots, immunofluorescence localization, in vitro ATPase and aggregation-suppression assays with recombinant protein

   PMID:21191678

   Open questions at the time

   • Did not identify physiological client proteins
   • No in vivo essentiality or phenotype established
   • Mechanism of substrate handoff to PfHsp70-1 not resolved
2. 2020 High

   Quantitative biophysical comparison against human orthologs was needed to explain why the parasite chaperone pair might be functionally distinct and drug-targetable.

   Evidence In vitro folding, aggregation-inhibition and disaggregase assays, SPR kinetics, and SAXS on recombinant PfHSP40/PfHSP70-1

   PMID:32893851

   Open questions at the time

   • Superior in vitro activity not linked to a specific parasite client
   • Dimer/complex architecture not resolved at atomic resolution
   • In vivo relevance of superior kinetics untested
3. 2021 Medium

   Identifying farnesylation as a post-translational modification addressed how HSP40 associates with membranes and which pathways its lipidation controls.

   Evidence PTM mapping, membrane fractionation, proteomics of farnesylation-deficient mutants, and temperature-stress survival assays

   PMID:34182772

   Open questions at the time

   • Specific clients whose interaction depends on farnesylation not fully defined
   • Single lab
   • Enzymatic machinery adding the farnesyl group not characterized here
4. 2021 Low

   Measuring the relative affinities of HSP40 for different parasite Hsp70s refined which Hsp70 partner it preferentially engages.

   Evidence Surface plasmon resonance binding affinity measurements against PfHsp70-1 and PfHsp70-z

   PMID:34141839

   Open questions at the time

   • Single dataset paper with no functional follow-up reported
   • Biological consequence of affinity differences not tested
   • Not validated by an orthogonal binding method
5. 2024 High

   Identifying PfR2 as a specific client linked the chaperone activity to a concrete essential process — dNTP synthesis for DNA replication — and validated the HSP40–Hsp70 interface as a drug target.

   Evidence Reciprocal co-immunoprecipitation, small-molecule (116-9e) perturbation, dNTP quantification, growth and drug-synergy assays in strain 3D7

   PMID:40938117

   Open questions at the time

   • Structural basis of PfR2 recognition unresolved
   • Full client repertoire beyond PfR2 unknown
   • Whether farnesylation modulates PfR2 handling not tested
6. 2025 High

   Conditional knockdown established essentiality and demonstrated that HSP40 acts specifically in heat-shock survival and DNA-replication support rather than in general proteotoxic stress responses.

   Evidence Tunable conditional knockdown, flow-cytometry cell-cycle analysis, untargeted proteomics, and drug-sensitivity assays

   PMID:40627776

   Open questions at the time

   • Molecular link between chaperone loss and DNA-replication downregulation only correlative via proteomics
   • Client set responsible for thermotolerance beyond PfR2 not enumerated
   • Sexual-stage/transmission role not assessed

• The full client repertoire of HSP40 and the structural basis by which it selects and delivers substrates such as PfR2 to PfHsp70-1 remain to be defined.
• No atomic-resolution structure of the HSP40–PfHsp70-1 or HSP40–PfR2 complex
• Clients other than PfR2 not systematically mapped
• How farnesylation-dependent membrane targeting intersects with client selection is unresolved